AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall

Friday, AbbVie Inc ABBV reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion. The immunology portfolio generated $6.95 billion in sales, down 12.3%.…#abbvieincabbv #eps #humira #rinvoq #imbruvica #venclexta #abbvie #immunogenincimgn #neuroscience #botoxtherapeutic
Source: Reuters: Health - Category: Consumer Health News Source Type: news